First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Mirion Technologies: the story is balanced — Nuclear power plant life extension and uprating projects - drives instrumentation upgrades and multi-year service…
★ Analysts see FY2026 revenue reaching $1.1B — +23.0% growth in a single year.
What Moves the Stock
1Nuclear power plant life extension and uprating projects - drives instrumentation upgrades and multi-year service contracts worth $2-5M per plant
2Medical isotope production capacity additions - new Mo-99 production facilities and radiopharmaceutical manufacturing expansions require specialized detection equipment
3Defense budget allocations for radiological/nuclear detection programs - border security portal deployments and military CBRN (chemical, biological, radiological, nuclear) equipment procurement
4Acquisition announcements and integration execution - company has pursued roll-up strategy in fragmented radiation detection market
5Nuclear decommissioning project awards - large-scale plant closures generate $10-30M equipment and services opportunities over 5-10 year timelines
6Medical radiation detection systems (~40% of revenue) - dosimetry badges, area monitors, and sterilization equipment for hospitals and medical device manufacturers
7Nuclear power plant instrumentation (~35% of revenue) - reactor monitoring systems, personnel dosimeters, and environmental surveillance equipment with recurring calibration services
8Industrial and defense applications (~25% of revenue) - border security radiation portals, laboratory spectroscopy systems, and contamination detection for decommissioning projects
growth - The stock attracts growth investors focused on nuclear energy renaissance themes, medical technology expansion…
Rising rates create modest headwinds through higher financing costs on the company's $370M net debt position (0.68 debt/equity ratio)…
Watch on earnings: Global nuclear power capacity additions and uprating announcements - indicates addressable market expansion particularly in China, India, and emerging markets, US Nuclear Regulatory Commission license renewal applications - 20-year extensions drive $3-5M instrumentation upgrade cycles per plant, Medical isotope supply chain developments - Mo-99 reactor outages or new production facilities impact demand for radiation detection in radiopharmaceutical manufacturing.
One Sentence Summary:
Mirion Technologies: the story is balanced — nuclear power plant life extension and uprating projects - drives instrumentation upgrades and multi-year service contracts worth $2-5m.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.